{
"id":"mk19_b_hm_t25",
"number":25,
"bookId":"hm",
"title":{
"__html":"Cellular Transfusion Product Modifications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7d8815",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 25. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t25"
}
]
},
"Cellular Transfusion Product Modifications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8af1f1",
"class":"col hd l",
"children":[
"Modification"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49ae69",
"class":"cell txt l",
"children":[
"Leukoreduction",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
": decreases number of leukocytes present in transfused erythrocytes or platelets"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0fbb16",
"class":"cell txt l",
"children":[
"Reduces class I HLA alloantibody production and subsequent platelet transfusion refractoriness."
]
},
" ",
{
"type":"p",
"hlId":"9aac09",
"class":"cell txt l",
"children":[
"Decreases febrile nonhemolytic transfusion reactions."
]
},
" ",
{
"type":"p",
"hlId":"062dee",
"class":"cell txt l",
"children":[
"Decreases transmission of CMV."
]
},
" ",
{
"type":"p",
"hlId":"af5e88",
"class":"cell txt l",
"children":[
"Leukoreduction cannot be relied on to prevent transfusion-associated GVHD."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0fc283",
"class":"cell txt l",
"children":[
"Irradiation: prevents replication of lymphocytes and circulating stem cells present in erythrocyte or platelet products"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20734a",
"class":"cell txt l",
"children":[
"Prevents transfusion-associated GVHD, which is mediated by donor lymphocytes."
]
},
" ",
{
"type":"p",
"hlId":"317391",
"class":"cell txt l",
"children":[
"Indicated in patients with severe immunodeficiency, whether inherited or acquired or following chemotherapy."
]
},
" ",
{
"type":"p",
"hlId":"c121a8",
"class":"cell txt l",
"children":[
"Indicated in immunocompetent patients receiving HLA-matched platelets or transfusions from relatives."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"458caf",
"class":"cell txt l",
"children":[
"Washing: removes proteins remaining in the plasma of erythrocyte and platelet products"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"383837",
"class":"cell txt l",
"children":[
"Used in patients with a history of severe/recurrent allergic reactions, IgA deficiency (when IgA-deficient donors are unavailable)."
]
},
" ",
{
"type":"p",
"hlId":"cd60fe",
"class":"cell txt l",
"children":[
"Reduces the amount of potassium transfused for patients who are at high risk for hyperkalemia."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CMV = cytomegalovirus; GVHD = graft-versus-host disease."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"More than 80% of blood banks in the United States adhere to universal leukoreduction. For those that do not, leukoreduction should be performed for patients who undergo chronic transfusion, those with a history of a febrile hemolytic transfusion reaction, patients who are potential candidates for or recipients of a solid-organ or hematopoietic stem cell transplant, and immunocompromised recipients who are CMV seronegative."
]
]
}